Phase II trial of subcutaneous injections of human recombinant interleukin-2 for the treatment of mycosis fungoides and Sézary syndrome.

MLA

Querfeld, Christiane, et al. “Phase II Trial of Subcutaneous Injections of Human Recombinant Interleukin-2 for the Treatment of Mycosis Fungoides and Sézary Syndrome.” Journal of the American Academy of Dermatology, vol. 56, no. 4, Apr. 2007, pp. 580–83. EBSCOhost, https://doi.org/10.1016/j.jaad.2006.08.067.

APA

Querfeld, C., Rosen, S. T., Guitart, J., Rademaker, A., Foss, F., Gupta, R., & Kuzel, T. M. (2007). Phase II trial of subcutaneous injections of human recombinant interleukin-2 for the treatment of mycosis fungoides and Sézary syndrome. Journal of the American Academy of Dermatology, 56(4), 580–583. https://doi.org/10.1016/j.jaad.2006.08.067

Chicago

Querfeld, Christiane, Steven T Rosen, Joan Guitart, Alfred Rademaker, Francine Foss, Rohit Gupta, and Timothy M Kuzel. 2007. “Phase II Trial of Subcutaneous Injections of Human Recombinant Interleukin-2 for the Treatment of Mycosis Fungoides and Sézary Syndrome.” Journal of the American Academy of Dermatology 56 (4): 580–83. doi:10.1016/j.jaad.2006.08.067.